Jacob Johnson

Is that something that is contemplated in the 1% headwind from the loss of those customers?

Do you think this is what you're seeing in Healthcare Capital Equipment is just related to timing of orders? Is it kind of specific to 3Q

could unpack the trends you're seeing in that bioprocessing end market and what that could mean as we look out over for AST

can you frame up the magnitude of that loss, just how much of a headwind that was to margins in the segment

Can you just talk about how Wilson Wolf trended in the quarter and any benefit on the other income line from them

can you just help us think through kind of any one-time items in one queue and then any benefits from cost savings as we get into the rest of the year?

Was this kind of a deliberate change in strategy that happened at some point, or is this just opportunistic